Risk factors of repetitive thoracentesis of malignant pleural effusion in naive non-small cell lung carcinoma

I Putu Surya Sujana; Ida Ayu Jasminarti Dwi Kusumawardani; Ni Wayan Candrawati; Ida Bagus Ngurah Rai; I Gede Ketut Sajinadiyasa; Ni Luh Putu Eka Arisanti; I Gusti Ngurah Bagus Artana

doi:10.53730/ijhs.v6nS9.13810

Authors

I Putu Surya Sujana Department of Pulmonology and Respiratory, Faculty of Medicine, Udayana University, Prof. Dr IGNG Ngoerah Central General Hospital Denpasar, Bali, Indonesia, 80114
Ida Ayu Jasminarti Dwi Kusumawardani
jasminarti@unud.ac.id
Department of Pulmonology and Respiratory, Faculty of Medicine, Udayana University, Prof. Dr. IGNG Ngoerah Central General Hospital Denpasar, Bali, Indonesia, 80114
Ni Wayan Candrawati Department of Pulmonology and Respiratory, Faculty of Medicine, Udayana University, Prof. Dr. IGNG Ngoerah Central General Hospital Denpasar, Bali, Indonesia, 80114
Ida Bagus Ngurah Rai Department of Pulmonology and Respiratory, Faculty of Medicine, Udayana University, Prof. Dr. IGNG Ngoerah Central General Hospital Denpasar, Bali, Indonesia, 80114
I Gede Ketut Sajinadiyasa Department of Pulmonology and Respiratory, Faculty of Medicine, Udayana University, Prof. Dr. IGNG Ngoerah Central General Hospital Denpasar, Bali, Indonesia, 80114
Ni Luh Putu Eka Arisanti Department of Pulmonology and Respiratory, Faculty of Medicine, Udayana University, Prof. Dr. IGNG Ngoerah Central General Hospital Denpasar, Bali, Indonesia, 80114
I Gusti Ngurah Bagus Artana Department of Pulmonology and Respiratory, Faculty of Medicine, Udayana University, Prof. Dr. IGNG. Ngoerah Central General Hospital Denpasar, Bali, Indonesia, 80114

Keywords:

Repetitive thoracentesis, Malignant Pleural Effusion, NSCLC

Abstract

Almost 40% of Non Small Cell Lung (NSCLC) patients develop Malignant Pleural Effusion (MPE). Nowadays, clinicians prefer to perform a repetitive thoracentesis rather than a definitive procedure, which causes pleural loculations and inflammation. This study aimed to identify risk factors of repeated thoracentesis MPE in NSCLC. This was an observational analytic study with a retrospective cohort design held at Prof.Dr. I.G.N.G Ngoerah General Hospital from January 2018 to June 2022. There were 95 subjects who participated in this study. The median time of repetitive thoracentesis MPE in NSCLC is 3 days (95% CI 1,9-4). The difference in location tumor in the peripheral was 3 days (2.25-3.74) while in the central was 7 days (4.24-9.75), p=0.21. The difference in histology type, Adenocarcinoma was 3 days (1.86-4.13) while squamous cell carcinoma was 4 days (2.53-5.46), p=0.69. Pleural fluid cytology positive was 6 days (2.78-9.22) while negative was 3 days (1.83-4.16), p=0.51. The EGFR mutation positive was 4 days (2.48-5.52) while negative 3 days (1.68-4.31), p=0.78. LDH levels ≥821 IU/L was 3 days (1.49-4.50) while <821 IU/L was 4 days (2.32-5.67), p=0.81. The size of pleural effusion massive was 3 days (1.88-4.11) while non-massive was 4 days (0.93-7.06), p=0.49.

Downloads

Download data is not yet available.

References

Audra J. Schwalk, MD, MBA, David E. Ost, MD, MPH, Sahara N. Saltijeral, MS. 2020. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients with Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA DOI: https://doi.org/10.1016/j.chest.2020.10.081.

Banka R,George V, Rahman NM. 2020. Multidisciplinary approaches to the management of malignant pleural effusions: a guide for the clinician. Expert Review of Respiratory Medicine, doi:10.1080/17476348.2020.1793672

Cakir E, Demirag F, Aydin M, Erdogan Y. 2011. A review of uncommon cytopathologic diagnoses of pleural effusions from a chest disease center in Turkey. Cytojurnal, 8(13). doi: 10.4103/1742-6413.83026

Cheng D, Liang B, Li YH. 2012. Application of MMP-7 and MMP-10 in assisting the diagnosis of malignant pleural effusion. Asian Pac J Cancer Prev. 2012;13:505–9.

Chen Y, Mathy N, Lu H. 2018. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non small cell lung cancer (Review). Molecular Medicine Reports. 17, 8019-8030. doi:10.3892/mmr.2018.8922

Elsaka, O., Noureldean, M. A., Gamil, M. A., Tarek Ghazali, M., Abd Al-Razik, A. H. and Hisham, D. 2022. Etiology, Investigations, and Treatment in Cases of Non-Small Cell Lung Cancer”, Asian Basic and Applied Research Journal, 5(2), pp. 22-48. Available at: https://www.globalpresshub.com/index.php/ABAARJ/article/view/1462

Fan JL, Zhang W, Lei1 C, Qiao B, Liu Q, Chen Q, et al. 2015. Vascular endothelial growth factor polymorphisms and lung cancer risk. Int J Clin Exp Med. 8(4):6406-6411 www.ijcem.com /ISSN:1940-5901/IJCEM0003921 Original Article

Fariha Ramadhaniah. 2016. Gambaran Kanker Paru Karsinoma Bukan Sel Kecil dengan Efusi Pleura. Bagian Penelitian dan Pengembangan, RS Kanker Dharmais, Jakarta. J Respir Indo Vol. 36 No. 2 April 2016

Farah Fatma et al. 2018. Buku Ajar Paru : Kanker Paru. Departemen /SMF Pulmonologi dan Ilmi Kedokteran Respirasi Universitas Airlanga. 2018

Ferlay J, Colombet M, Soerjomataram. 2020. Global and Regional Estimates of the Incidence and Mortality for 38 Cancers: GLOBOCAN 2020. Lyon: International Agency for Research on Cancer/World Health Organization.

Grosu HB, Molina S, Casal R. 2019. Risk factors for pleural effusion recurrence in patients with malignancy. Respirology. 24(1):76-82.

Guo H, Wan YY, Tian GY, Liu QH, Kang YM, Li YY,, et al. 2011. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy. Received September 21, 2011; Accepted November 9. DOI: 10.3892/or.2011.1559

Hariyanto, Wahyuni; Wulandari, Laksmi; Pradjoko, Isnu; Soegiarto, Gatot. 2020. Comparison of Vascular Endothelial Growth Factor-A (VEGF-A) Level in Pleural Fluid of Patients with Malignant and Nonmalignant Pleural Effusion. Indian Journal of Surgery,doi:10.1007/s12262-020-02204-z

Jany B, Welte T. 2019. Pleural effusion in adults etiology, diagnosis, and treatment. Dtsch Arztebl Int.116: 377–86. DOI: 10.3238/arztebl.2019.0377

Liang J, Yu X, Liu X, Sun D, Liu H, Hu W, Li Y. 2009. Vascular endothelial growth factor polymorphisms and risk of lung cancer. The Chinese-German Journal of Clinical Oncology. 8(5), 269–272. doi:10.1007/s10330-009-0054-2

Lin JB, Lai FC, Li X, et al. 2017. Sequential treatment strategy for malignant pleural effusion in nonsmall cell lung cancer with the activated epithelial grow factor receptor mutation. J Drug Target. 25(2):119-124.

Murthy, P., Ekeke, C. N. and Russell, K. L. 2019. Making cold malignant pleural effusions hot : driving novel immunotherapies, OncoImmunology, 8(4), p. e1554969.

Musso V, Diotti C, Palleschi A, Tosi D, Aiolfi A, Mendogni P. 2021. Management of Pleural Effusion Secondary to Malignant Mesothelioma. J. Clin. Med. 10, 4247. Academic Editors: Filippo Lococo, Andrea Billè and Giuseppe Cardill https://doi.org/10.3390/ jcm10184247.

Morgensztern D, Waqar S, Subramanian J, Gao F, Trinkaus KM, Govindan R. 2012. Prognostic significance of tumor size in patients with stage III non–small-cell lung cancer a surveillance, Epidemiology, and End Results (SEER) Survey from 1998 to 2003. J Thorac Oncol. 7(10):1479–84

Ost DE, Niu J, Zhao H, Grosu HB, Giordano SH. 2018. Quality Gaps and Comparative Effectiveness of Management Strategies for Recurrent Malignant Pleural Effusions. Chest. 153(2):438-452.

Rivera, M. Patricia; Mehta, Atul C.; Wahidi, Momen M. 2013. Establishing the Diagnosis of Lung Cancer. Chest, 143(5), e142S–e165S. doi:10.1378/chest.12-2353

Roberto F. Casal, Macarena R. Vial, Russell Miller, Lakshmi Mudambi. 2017. What Exactly Is a Centrally Located Lung Tumor? Results of an Online Survey. Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. American Thoracic Society Vol 14, No 1, pp 118–123. DOI: 10.1513/AnnalsATS.201607-568BC

Samah S, Sileem AE, El-Fakharany KM. 2015. Pleural fluid CRP, LDH, and pH as predictors of successful pleurodesis in malignant pleural effusions. Egyptian Journal of Chest Diseases and Tuberculosis. 64(3), 593–599. doi:10.1016/j.ejcdt.2015.05.003

Schwalk AJ, Ost DE, Saltijeral SN, De La Garza H, Casal RF, Jimenez CA, et. al. 2020. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients with Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.

Shu J, Sun G, Liu H, Liu J. 2007. Clinical utility of vascular endothelial growth factor in diagnosing malignant pleural effusions. Acta Oncol 46(7):1004–1011

Smits AJJ, Kummer A, Hinrichs JWJ, Herder GJM, Scheidel-Jacobse KC, Jiwa NM,, et al. 2012. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol. 35(3), 189–196. doi:10.1007/s13402-012-0078-4

Stathopoulos, G. T. and Kalomenidis, I. 2012. Malignant pleural effusion, Am J Respir Crit Care Med, 186(6), pp. 487–492.

Syahruddin E, Pratama AD, Arief N. 2010. A Retro-spective Study: Clinical and diagnostic charac-teristics in advanced stage of lung cancer patients with pleural effussion in Persahabatan Hospital 2004 – 2007. J Respir Indo. 2010; 30(3):146-51.

Thomas R, Francis R, Davies HE, Lee YC, Gary. 2014. Interventional therapies for malignant pleural effusions: the present and the future. Respirology. 19(6), 809–822. doi:10.1111/resp.12328

Verma A, Chopra A, Lee YW, et al. 2016. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma. Current drug discovery technologies. 2016;13(2):68-76.

Xu CH, Yu L, Zhan P, Zhang Yu. 2014. Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients. Eur J Med Res. 19(1): 23.

Yang F, Qin Z, Shao C, Liu W, Ma L, Shu Y, & Shen H. 2018. Association between VEGF Gene Polymorphisms and the Susceptibility to Lung Cancer: An Updated Meta-Analysis. BioMed Research International. 1–16. doi:10.1155/2018/9271215.